CARD11 Inhibitors
Chemical inhibitors of CARD11 operate through various mechanisms to modulate the activity of this protein. Lenalidomide acts by promoting the ubiquitination and subsequent degradation of IκB kinase (IKK). The degradation of IKK prevents the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a critical downstream target of CARD11 signaling. Similarly, Bortezomib disrupts the NF-κB pathway by inhibiting the proteasome responsible for degrading IκB, an inhibitor of NF-κB, thus preventing NF-κB activation. Thalidomide also modulates CARD11 activity by preventing IκB degradation, leading to suppression of NF-κB. Ibrutinib, on the other hand, binds irreversibly to Bruton's tyrosine kinase (BTK), an enzyme upstream of CARD11 in the B-cell receptor signaling pathway, resulting in reduced CARD11 signaling.
Other inhibitors target various kinases that interact with CARD11 signaling pathways. Sorafenib inhibits multiple protein kinases, including those in the MAPK pathway, which interacts with CARD11 signaling, thereby reducing CARD11-mediated NF-κB activation. Sunitinib and Dasatinib inhibit tyrosine kinases that are involved in the activation of CARD11, leading to decreased CARD11-mediated signaling. Rapamycin and AZD8055 inhibit mTOR, a pathway connected to CARD11 function, which in turn reduces the activity of CARD11. U0126 interrupts the CARD11 signaling cascade by inhibiting MEK1/2, kinases in the MAPK/ERK pathway. Similarly, SP600125 inhibits JNK, part of stress-activated protein kinase pathways that influence CARD11 activity. Lastly, Ixazomib, like Bortezomib, inhibits the proteasome, leading to an accumulation of IκB and inhibition of the NF-κB pathway, culminating in a reduction of CARD11 dependent processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Lenalidomide inhibits the activity of CARD11 by promoting the ubiquitination and degradation of IκB kinase (IKK), thereby preventing the activation of NF-κB which is a downstream target of CARD11 signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib disrupts the NF-κB pathway by inhibiting the proteasome, which is responsible for the degradation of IκB, an inhibitor of NF-κB. This results in suppression of NF-κB activation, a pathway in which CARD11 is known to be involved. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits several protein kinases, including those involved in the MAPK pathway, which interacts with CARD11 signaling. By inhibiting these kinases, Sorafenib can reduce CARD11-mediated activation of the NF-κB cascade. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Sunitinib targets tyrosine kinases that participate in the signaling pathways that intersect with CARD11 function. Inhibition of these kinases can lead to a decrease in CARD11-mediated signaling events. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits Src family kinases which are involved in the activation of CARD11. By inhibiting these kinases, Dasatinib can attenuate the signaling pathway leading to CARD11 activity. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib irreversibly binds to Bruton's tyrosine kinase (BTK), an enzyme in the B-cell receptor signaling pathway which is upstream of CARD11; its inhibition can reduce CARD11 mediated signaling in B cells. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to mTOR, thereby inhibiting the mTOR pathway which is connected to CARD11 function. This inhibition can reduce the activity of CARD11, as mTOR signaling is necessary for optimal CARD11 function. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide can inhibit the NF-κB pathway through the prevention of IκB degradation, which leads to the suppression of CARD11 downstream activity. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is a potent inhibitor of mTOR kinase activity, which is involved in pathways that regulate CARD11 function. By inhibiting mTOR, AZD8055 can reduce the functional activity of CARD11. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are kinases in the MAPK/ERK pathway that has been shown to interact with CARD11 signaling. Inhibition of MEK1/2 can lead to reduced CARD11-mediated signaling. | ||||||